Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

approximately $25 million and restructuring charges of approximately

$15 million. There could be additional charges excluded from the

Company's GAAP net loss, to arrive at non-GAAP net income, which are

dependent on unknown future events and are difficult to predict and

estimate at this time.

Contacts:

Kyle Kuvalanka (investors) Jennifer Snyder (media)

(617) 761-4734 (617) 444-1439

Millennium Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

(in thousands, except per share

amounts)

Revenues:

Net product sales $70,360 $53,161 $191,550 $165,320

Revenue under strategic

alliances 10,628 17,196 38,168 82,990

Royalties 41,344 33,737 116,617 98,382

Total revenues 122,332 104,094 346,335 346,692

Costs and expenses:

Cost of sales 6,931 6,730 17,668 36,660

Research and development (Note 1) 72,551 73,436 217,162 235,343

Selling, general and

administrative (Note 1) 42,949 34,365 129,506 107,221

Restructuring 1,667 1,352 13,050 5,737

Amortization of intangibles 8,488 8,488 25,462 25,462

Total costs and expenses 132,586 124,371 402,848 410,423

Loss from operations (10,254) (20,277) (56,513) (63,731)

Other income (expense):

Investment in
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 US-Australian drug ... ) today confirmed it is committed to progressing its ... soon as practicable and to ensure the Company delivers ... Executive Officer, Iain Ross , said the Company ... the lead pre-clinical programs, discovery programs and academic partnerships ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the leading ... 2nd generation cell therapy POD® design. The 2nd generation portfolio not only delivers ... new POD® design. , “G-CON first offered our miniPOD CT product line ...
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  Pfenex ... quarter 2015 financial results will be released on Thursday, ... 8:30 am Eastern Time, Pfenex management will host a ... a business update.  A press release outlining the financial ... to the call. Please call 1-866-376-8058 (US) ...
(Date:7/29/2015)... ... 29, 2015 , ... Finding gooey or crusty material in the corner of ... a considerable number of terms in popular use to describe it, ophthalmologists call it ... of mucus, blood cells, skin cells and dust, but until now there has been ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4
... Aug. 24 Advanced Instruments has introduced a next-generation Web ... purchasing osmometers, cryoscopes, and microbiological laboratory instruments. The site, ... , was developed from the perspective of the Web ... scientific materials, and technical support. , , ...
... , BASKING RIDGE, N.J., Aug. 24 ... the development of antithrombotic therapeutic aptamers with active control ... the first Phase I study of a subcutaneous administration ... a double-blind, randomized, placebo-controlled, single ascending dose study to ...
... , SAN DIEGO, Aug. 24 ... announced that Mark Booth has joined the Company as Chief ... commercial and business development experience to Orexigen. Most recently ... where he presided over the commercial, medical and scientific affairs, ...
Cached Biology Technology:Advanced Instruments Introduces Next-Generation Web Site 2Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System 2Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer 2
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... A scientific project funded by the BBVA Foundation and conducted ... (CSIC) explored around 100 kilometers of practically uncharted Atlantic beach ... the years 2006 and 2007. In the course of their ... hope for the survival of the leatherback turtle. This species ...
... , Now that Olympia is approaching, the Chinese authorities ... large cities with different measures. For example, the car ... ordered not to use 70 percent of all company ... even or odd days - in accordance with their ...
... A new study by researchers at The University of Texas ... to continue the current practice of retesting women during their ... tested positive for the infection previously. Group B Streptococcus, ... harmless to carriers but in some cases can be deadly ...
Cached Biology News:GKSS membranes reduce air pollution in Beijing 2Recurrence of group B strep high in subsequent pregnancies, say UT Houston obstetricians 2
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... you to store and manage very large ... secure central relational database. Storing and managing ... resource for clone tracking and enables you ... analysis. LabShare software integrates seamlessly with Invitrogen's ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
Biology Products: